Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells

KING OF PRUSSIA, Pa., Oct. 31, 2023 /PRNewswire/ — SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit. The presentation will highlight the discovery and characterization of SMARCA2 heterobifunctional degraders demonstrating selective SMARCA2 degradation leads to targeted growth inhibition of SMARCA4 mutant cancer cell lines, and share results of in vivo efficacy in a solid tumor xenograft model.

"We are pleased to present the first in vivo data on our potential best-in-class orally available selective SMARCA2 degraders to the scientific and pharmaceutical community participating at this year’s TPD Summit in Boston," said Zhihua Sui, Ph.D., Chief Scientific Officer, SK Life Science Labs. "Our compounds have shown robust anti-tumor efficacy in vivo and our current oral leads have demonstrated potent selective degradation of SMARCA2 and selective inhibition of proliferation of SMARCA4 mutated cancer cells. SMARCA4 is mutated in many cancers including non-small cell lung carcinoma, colon adenocarcinoma, bladder, and endometrial cancer."

Located in King of Prussia, Pennsylvania, SK Life Science Labs is an R&D company leveraging protein degradation to target the undruggable and elicit novel disease-modifying mechanism of action. SK Life Science Labs integrates its AI-enabled target ID platform, protein degrader discovery and development expertise, and MOPED™ molecular glue screening platform to identify and advance novel protein degraders.

"Today’s presentation unveils new data that showcase SK Life Science Labs’ unique approach to discovering compounds with the potential to change the future of cancer therapeutics," said Donghoon Lee, President and CEO of SK Biopharmaceuticals, SK Life Science Inc., and SK Life Science Labs. "Since acquiring SK Life Science Labs earlier this year, we have been focused on leveraging the company’s R&D capabilities and supporting its promising programs. We are very proud of our team’s accomplishments and look forward to continuing to push innovation forward so that we can maximize the potential of our pipeline."

Details of SK Life Science Labs Presentation at the 6th Annual TDP Summit:

Title: SMARCA2 Degraders for the Treatment of Solid Tumors

– Presenter: Jose Clemente, Ph.D., Senior Director of Biology, SK Life Science Labs
– Track: Preclinical Development
– Date/Time: Tuesday, October 31, 2023; 3:10 – 3:40 p.m. ET

About SK Life Science Labs
SK Life Science Labs (formerly Proteovant Therapeutics) exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases. Protein degradation harnesses the human body’s innate cellular machinery by way of the UPS to identify and mark disease-causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered undruggable. SK Life Science Labs integrates its AI-enabled target ID platform, degrader drug-hunting expertise, and MOPED™ molecular glue screening platform to advance novel protein degraders. As of August 11, 2023, SK Life Science Labs is part of SK Biopharmaceuticals.

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals is a global biotech company focused on the research, development, and commercialization of treatments to help people living with central nervous system (CNS) disorders and change the future of cancer care. Together with its U.S. subsidiary, SK Life Science, Inc., SK Biopharmaceuticals has a pipeline of eight compounds in development. Both companies are part of SK Group, one of the largest conglomerates in Korea and one of TIME’s 100 Most Influential Companies of 2023. For more information, please visit www.skbp.com/eng.

SK Biopharmaceuticals’ parent company SK Inc. continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit www.sk-inc.om/en.

SK Biopharmaceuticals
Investor Relations:
Cho Hyoungrae

Public Relations:
H. Park
Lim Soohui
[email protected]

SK Life Science Labs & SK Life Science
Dina Albanese
[email protected] 

Source : SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ — Amorepacific has secured a new growth engine in the global market by acquiring additional shares of COSRX. With this further stake acquisition, COSRX will be integrated as a subsidiary of Amorepacific.

Amorepacific incorporates COSRX as a subsidiary through additional stake acquisition.

Today, Amorepacific announced through the disclosure that it will acquire 288,000 remaining shares held by COSRX’s largest shareholder and related parties for 755.1 billion won. In September 2021, Amorepacific had previously acquired 38.4% of COSRX shares. At that time, they were granted a call option to purchase the remaining shares, which they have now decided to exercise. With this, Amorepacific is expected to own 93.2% of COSRX shares.

Founded in 2013, COSRX is a hypoallergenic skincare brand designed for sensitive skin. Centered around the ‘Advanced Snail’ line and ‘The RX’ line, it has experienced rapid growth, establishing itself as a rising global skincare titan. The company has shown an average annual sales growth rate of over 60% in the past three years, reporting 204.4 billion won in 2022. This year, in the first half alone, it has achieved 190.2 billion won in sales and 71.7 billion won in operating profit, continuing its sharp growth trend.

Moreover, it has expanded to around 140 countries, including North America, Southeast Asia, Europe, and Japan, with overseas sales accounting for over 90% of its total. Since it entered Amazon in 2018, essential products such as the ‘Advanced Snail 96 Mucin Power Essence’ have topped the Beauty & Personal Care category, particularly distinguishing itself in the North American market. Additionally, COSRX has been recognized as a brand with exceptional digital communication capabilities, evidenced by its TikTok challenge launched in 2022, which saw over 2.1 billion cumulative hashtag views.

After the equity investment in 2021, both companies co-developed and launched products such as ‘The Vitamin C 23 Serum’ and ‘The Retinol 0.1 Cream’ from COSRX’s next-generation core line, The RX, achieving success overseas. In this vein, Amorepacific plans to accelerate its global expansion through multifaceted collaboration with COSRX, which boasts strong global competitiveness.

Seunghwan Kim, CEO of Amorepacific Corporation, stated, "We are thrilled that COSRX, which has shown rapid growth through differentiated products and marketing based on an exceptional understanding of digital channels, has become a part of our group." He further revealed, "Moving forward, we aim to amplify COSRX’s unique strengths while also integrating Amorepacific’s vision and business management expertise to develop it into a captivating brand that global customers will love."

Source : Amorepacific Incorporates COSRX as a Subsidiary through Additional Stake Acquisition

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

TAIPEI, Oct. 31, 2023 /PRNewswire/ — YU XUAN FOOD CO., LTD. has recently announced the launch of their in-house brand, "Jin Tai-ZI," with a primary focus on showcasing high-quality Taiwanese food products, particularly dry noodle offerings, while actively expanding into international markets. The Jin Tai-ZI product range includes items such as white fungus beverage, various noodles, chili products, brown sugar, and traditional herbal teas, all crafted with all-natural, top-tier ingredients to ensure consumers enjoy the very best in culinary experiences.

With over three decades of experience, YU XUAN FOOD has established itself as a leading distribution and export company in Taiwan. They act as authorized distributors for various renowned domestic food manufacturers, including Yi-Mei, Uni-President, Hwa Yuan, and Want Want, to name a few. This positions YU XUAN FOOD as an ideal one-stop solution for consumers, offering a vast array of product choices in a single order.

YU XUAN FOOD‘s service portfolio encompasses domestic trade, international trade, cross-strait trade, and the supply of a wide range of shelf-stable food products. Their competitive edge lies in offering diverse product options, helping international importers explore new markets and alleviate inventory pressure. Furthermore, they pride themselves on providing end-to-end solutions, from sourcing to container shipping, labeling, container loading, delivery, and customs clearance, all of which help international importers reduce procurement costs.

Since 2016, YU XUAN FOOD has consistently expanded its business and actively sought new market opportunities. In 2011, they established a subsidiary in Xiamen, China, which marked the beginning of significant export operations, leading to a rapid expansion of their international footprint. In 2017, they introduced their proprietary brand, Jin Tai-ZI, which focuses on traditional Taiwanese noodle products such as sun-dried knife-cut noodles from Tainan and Guan Miao noodles. They also offer other products like White Fungus beverages and chili sauce, all made from premium Taiwanese agricultural products while adhering to a 30-year-old traditional crafting process to guarantee high quality and chewy textures.

One of the flagship products of the Jin Tai-ZI brand is their dry noodles. These noodles are crafted using high-quality wheat flour and traditional techniques, preserving the authentic taste and texture of Taiwanese cuisine. Notably, their production process includes a unique sun-drying step, ensuring that the noodles absorb ample sunlight and air, resulting in a pleasantly chewy that remains consistent throughout the cooking process.

Jin Tai-ZI dry noodles stand out for their excellent flavor and exceptional resistance to overcooking. Compared to regular noodles, Jin Tai-ZI dry noodles can be boiled for an extended period without becoming overly soft or clouding the soup, making them an ideal companion for flavor noodles, noodle dishes, and hot pots.

YU XUAN FOOD has effectively introduced Jin Tai-ZI dry noodles to the international market. These delectable noodles have already made their way to numerous countries and regions, including Hong Kong, mainland China, Singapore, Italy, the UK, and more. Their commitment to providing end-to-end services, from sourcing to container shipping, has assisted international importers in reducing procurement costs and solidified their reputation as a trusted supplier.

The introduction of the Jin Tai-ZI brand marks a significant milestone for YU XUAN FOOD in the food trade sector. The brand will continue its strong push into the international market, offering global consumers the essence of traditional Taiwanese cuisine. Whether relishing a comforting bowl of noodle soup at home or savoring authentic Taiwanese flavors in a restaurant, Jin Tai-ZI dry noodles represent the tradition and quality of Taiwanese food, delivering a delightful culinary choice to consumers.

Source : Leading Food Trade Brand, YU XUAN FOOD, Unveils Self-Brand 'Jin Tai-ZI' with a Strong Emphasis on International Expansion and Premium Dry Noodle Products

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

KAOHSIUNG, Oct. 31, 2023 /PRNewswire/ — Asia Frozen Food Corp. (AFFC) has long been Taiwan’s largest exporter of frozen foods, with their flagship product, edamame, enjoying international acclaim. Recent data reveals that edamame exports have surpassed 2.6 billion New Taiwan Dollars, earning it the moniker of "Taiwan’s Green Gold." However, after dominating the Asian frozen food market for 56 years, Asia Frozen Food Corp. is now embarking on its next phase, aimed at achieving corporate sustainability and environmental responsibility.

Established in 1976, Asia Frozen Food Corp. has played a leading role in the food industry ever since. Headquartered in Taiwan, the company boasts manufacturing facilities in both Taiwan and mainland China, producing frozen raw materials and natural chips. Additionally, they have sourcing branches for frozen raw materials in Thailand, Vietnam, mainland China and Indonesia. Asia Frozen Food Corp.’s factories employ cutting-edge technology for food processing and hold certifications such as HACCP, ISO, BRC, Halal, and Kosher.

Edamame, also known as Edamame Mukimame, derives its name from the Japanese term "Eda-beans on mame-branches" and has captivated snack enthusiasts worldwide. Asia Frozen Food Corp.’s meticulous freezing process brings forth the most convenient and delectable way to savor the natural goodness of edamame. Edamame is celebrated as a superfood due to its high protein and fiber content, offering numerous health benefits. Its popularity continues to soar globally, aligning with one of Asia Frozen Food Corp.’s core missions.

In pursuit of sustainability, Asia Frozen Food Corp. spares no effort. One of their future goals is to establish a zero-waste production model, promoting recycling and reuse. Moreover, by utilizing factory waste to generate energy, they aim to reduce production costs while contributing to the preservation of our planet’s resources. To ensure long-term agricultural sustainability, the company is committed to using organic fertilizer, safeguarding land quality for enduring operations.

Asia Frozen Food Corp. operates under the mission of "Love Earth, Love Life, and Love to Eat." They are dedicated to providing sustainable and healthy food for our planet and the generations to come. As they step into the next phase of their journey, Asia Frozen Food Corp. will continue to lead the food industry towards the realization of sustainable dreams.

Source : Asia Frozen Food Corp: The Miracle Maker of 'Taiwan's Green Gold' Sets Sights on Sustainability in Food Manufacturing

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Oct. 31, 2023 /PRNewswire/ — Reeracoen, a leading provider of human resource services in Singapore, has released the results of its latest survey, "What Singapore Workers Want". Conducted throughout July and August this year, the survey aimed to uncover the preferences and expectations of Singaporean workers and their career plans amid the evolving changes in Singapore’s economy.

The comprehensive four-part survey garnered 1,587 responses, seeking to provide a deeper understanding of what motivates Singaporean employees and their career plans. The findings shed light on the factors influencing their decisions, with significant implications for employers and workers.

In the first survey, "What Singapore Workers Want Most," the majority of the 293 respondents expressed a strong desire for Work-Life Balance (47%). This was closely followed by Remote Work (26%), Four-day Workweeks (19%), and Professional Development (8%). The second survey included monetary rewards as an option and revealed that Work-Life Balance still topped the list, with 57% of the 424 respondents choosing it, followed by Money (25%), Remote Work (10%), and Four-day Workweek (8%).

The third survey, conducted on 1 August, asked workers about their salary expectations. Most of the 425 respondents (54%) anticipated a 6% to 10% salary increase, while 28% expected a 1% to 5% raise. Only 13% expected their salary to remain the same, and a small percentage anticipated a pay cut (5%).

The series culminated in a final survey on 15 August, which asked if individuals were considering a job change before the end of the year. An overwhelming majority of the 445 respondents (73%) expressed their intent to change jobs. The remaining respondents answered No (12%), Maybe (12%), and I Don’t Know (3%).

The recurring themes of the first two surveys indicated a strong preference for work-life balance, followed by financial considerations. Subsequent surveys highlighted the anticipation of salary increases, prompting contemplation about job transitions in pursuit of better remuneration prospects.

Reeracoen, as a leading employment and recruitment firm, recognises the potential to bridge the gap between job seekers and employers by providing workforce insights. These insights can assist both parties in making informed decisions for a thriving and harmonious professional life.

Mr Kenji Naito, Reeracoen’s Group CEO, stated, "The surveys seem to indicate time and monetary rewards as main factors when Singapore workers consider employment. As part of their talent retention strategies, employers should remain sensitive to their employees’ preferences and financial well-being and strive to offer competitive packages to retain their top talents."

He continued, "The Singaporean workforce’s aspirations for better work-life balance and enhanced financial remuneration reflect the pressing need for companies to foster employee well-being and offer competitive compensation packages. This shift indicates a more nuanced and progressive approach to employment within the dynamic landscape of Singapore’s ever-evolving economy."

Reeracoen envisions that the survey findings will benefit two main groups:

Employers: Understanding these sentiments can help companies develop more effective staff retention strategies to retain their valuable workforce. Firms can use this data to re-evaluate their compensation strategies to stay competitive in retaining and attracting top talent. The survey findings also offer insights into talent acquisition. Singapore Workers: Workers can make informed career decisions with more knowledge about industry trends and shifts. With this knowledge, employees can confidently negotiate better compensation packages and seek employers aligned with their salary and career growth expectations.

Reeracoen’s commitment to providing holistic and beneficial matches between employers and prospective job seekers, based on understanding the evolving needs and expectations of the Singaporean workforce, sets the stage for a mutually advantageous employment landscape.

To access more valuable content and stay updated with Reeracoen, please visit the official website at https://www.reeracoen.sg/en/services/recruitment_solutions and follow on LinkedIn at https://www.linkedin.com/company/reeracoen-singapore-pte-ltd-/.

Reeracoen’s Group CEO, Mr Kenji Naito

About Reeracoen Singapore Pte Ltd

Reeracoen Singapore Pte Ltd is one of Singapore’s leading recruitment agencies. With our extensive networks, we effectively source and match high-calibre candidates to our partners. Our clients enjoy peace of mind knowing that as part of the Neo-career group, Reeracoen is committed to delivering the same Japanese professionalism and service quality across our ten offices in 6 Asian countries. For more information, visit https://www.reeracoen.sg/ and follow us on social media.

Source : Reeracoen Reveals What Singapore Workers Want in Latest Survey

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEONGNAM, South Korea and NEWTON, Mass., Oct. 31, 2023 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating the safety, tolerability, and antitumor activity of BBT-207 in non-small cell lung cancer (NSCLC) patients with EGFR mutations.

BBT-207, a novel epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is designed to inhibit the signaling pathway of EGFR with C797S mutations, which arises due to osimertinib (Tagrisso)-resistant mutations in NSCLC. The mutation results in a cysteine to serine change on amino acid 797 within the kinase domain sequence of the EGFR. Preclinically BBT-207 has shown activity against treatment-emergent complex EGFR mutations containing T790M and/or C797S as well as drug- naïve mutants providing a possibility to overcome resistance to prior TKIs.

The Phase 1/2 study (NCT05920135), an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BBT-207 in patients with NSCLC who have progressed following the use of at least one third-generation EGFR TKI, consists of three parts: dose escalation (Part 1), recommended phase 2 dose selection (Part 2), and dose expansion (Part 3). The study is expected to enroll approximately 92 patient participants who have advanced stage and refractory NSCLC with an activating EGFR mutation, documented partial response, complete response, or durable stable disease after the treatment of an EGFR TKI, and previous treatment with all standard therapeutic options and at least one third-generation EGFR TKI, including Osimertinib and Lazertinib.

The Phase 1a dose escalation cohort will determine the Recommended Dose Range (RDR), based on the totality of the data including toxicity/tolerability, efficacy, pharmacokinetic (PK), and pharmacodynamic (PD). During the Phase 1b RP2D selection stage, the safety monitoring committee will determine the Recommended Phase 2 Dose (RP2D) based on the totality of the data including overall safety, PK, PD, and preliminary antitumor activity including the percentage of patients with partial response (PR) or complete response (CR) based on RECIST Version 1.1. and duration of response (DOR). Finally, the Phase 2 dose expansion cohort will include assessments of preliminary anti-tumor activity utilizing the objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. In addition, detailed mutation profiles collected through liquid and tumor biopsy procedures will be analyzed after the study.

"We are highly encouraged to be able to initiate the first-in-patient study of BBT-207, which is expected to address unmet medical needs of advanced NSCLC patients with C797S mutations across the globe," said James Lee, CEO of Bridge Biotherapeutics.

Additional information about the clinical trial may be found at clinicaltrials.gov/study/NCT05920135.

Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths. Lung cancer is classified into two main groups: non-small cell lung cancers (NSCLC) and small cell lung cancers (SCLC), where NSCLC accounts for approximately 85% of all lung cancer diagnoses. In 2019, there were a combined 0.79 million diagnosed cases of NSCLC in men and women, aged 18 years and older, across the US, France, Germany, Italy, Spain, the UK, Japan, and urban China. The incidence of NSCLC is expected to increase at an annual growth rate (AGR) of 3.01% from 2019 to 2029, reaching 1.03 million cases in 2029[1].

In September 2023, Bridge Biotherapeutics announced the discontinuation of the development of BBT-176, another fourth generation EGFR TKI at the Phase 1a stage, dose escalation part. The company will remain committed to the development of a fourth generation EGFR TKI, while seeking to concentrate its capacity and financial resources on BBT-207.

STUDY TITLE: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment with EGFR TKI STUDY DESIGN: An open-label, Phase 1/2 study evaluating safety, tolerability, PK, PD, and preliminary antitumor activity of BBT-207 in patients with advanced NSCLC harboring EGFR mutation after treatment with EGFR TKI. The study will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion phases TEST PRODUCT: Oral administration of BBT-207 throughout a 21-day cycle for each phase STUDY OBJECTIVES: To evaluate the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207 in patients with advanced NSCLC harboring EGFR mutation after treatment with EGFR TKI

About Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at https://www.bridgebiorx.com/en/.

[1] GlobalData, Non-Small Cell Lung Cancer – Epidemiology Forecast Report to 2029, December 2020

Source : Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

As digital transformation (DX) continues to transform the financial sector, an information exchange was held to identify solutions and trends for data competitiveness.

SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI), hosted the Financial DX Meetup at the Conrad Hotel in Yeouido on the October 27. The event was attended by more than 30 key executives and opinion leaders from major commercial banks to share digital transformation trends and data analytics and AI strategies in the financial industry.

Altair Financial DX Meet-up

The event was themed "Open innovation: Innovation with data," and began with a welcome speech by Byunghee Choi, director of data analytics division, Altair Korea. The first presentation was given by Jinhyung Yang, director at PricewaterhouseCoopers (PwC), on the topic of "2024 Data Business Trends," which outlined six trends that will drive the year ahead.

Yang highlighted the following trends: accelerating cross-industry data convergence, differentiating ‘Smart Disclosure’ services, real-time data analytics and customer data platforms (CDP), adopting generative AI, expanding the application of big data, and enhancing data literacy. "Enhancing the ability to make data-driven decisions across the enterprise is key to competitiveness," said Yang.

Secondly, Jonghyun Yoon, consultant at Altair Korea, presented "RapidMiner: Fintech trends and changes in data analytics."

"As the adoption of AI and machine learning accelerates in the domestic financial sector, the importance of faster and more sophisticated analytical modelling will increase," said Yoon. "Altair RapidMiner supports no-code-based AutoML capabilities and can significantly improve an organization’s productivity by selecting the optimal modelling method."

Next, Jisu Kim, consultant at Altair Korea, presented "SLC: Unifying data languages to change analytics trends." Kim presented on accelerating the transition to open source in the financial industry. "Altair SLC is a solution that leverages the SAS language syntax and macros without the need a SAS language license, and integrate with open source like R and Python," said Kim.

Finally, Donggun Kim, senior consultant at Altair Korea, presented "Panopticon: Visualization analytics for real-time decision-making."

"Currently, the financial sector is promoting the establishment of customer data platforms (CDP) to provide differentiated customer experiences," said Kim. "Altair Panopticon supports rapid decision-making by dynamically visualizing data collected in real time, such as smart disclosure. It can be seamlessly embedded with existing systems such as customer data platforms to create synergies."

"Beginning with this event, we will hold an annual event for opinion leaders in the banking, financial services, and insurance industries to actively explore various cooperation opportunities with local financial companies," said Songsoo Moon, senior vice president of Asia Pacific, Altair.

Altair works with more than 4,000 banking, financial services, and insurance organizations, including 17 of the world’s top 20 investment banks, and is beginning to penetrate the domestic financial services market. Its flagship data analytics and AI platform, Altair RapidMiner, is used by more than 1.1 million users and 40,000 organizations in more than 150 countries.

About Altair
Altair is a global leader in computational science and artificial intelligence (AI) that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. For more information, visit https://www.altair.com/.

Media contacts 

Altair Corporate                                                                                 

Altair Investor Relations 

Jennifer Ristic                                                                                       

Monica Gould, The Blueshirt Group 

+1.216.849.3109                                                                                 

+1 212.871.3927 

[email protected]                                                             

[email protected] 

Altair Korea 

Iseul Jeong 

+82.10.7339.0740 

[email protected] 

Byunghee Choi, director of data analytics division, Altair Korea

Jinhyung Yang, director at PricewaterhouseCoopers (PwC)

Photo – https://mma.prnasia.com/media2/2260915/Altair_meetup.jpg?p=medium600
Photo – https://mma.prnasia.com/media2/2260916/Altair_Byunghee_Choi.jpg?p=medium600
Photo – https://mma.prnasia.com/media2/2260917/Altair_Jinhyung_Yang.jpg?p=medium600
Logo – https://mma.prnasia.com/media2/1421069/Altair_Logo.jpg?p=medium600

Source : Altair held Financial DX Meet-up for Financial Industry Undergoing Digital Transformation

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network